



Media Release: Sydney, Australia, 9 March, 2026.

Phebra launches Rapiblyk® in Australian healthcare settings

Australian pharmaceutical company Phebra has announced the launch of Rapiblyk® (landiolol hydrochloride), an ultra-short-acting, cardio-selective receptor antagonist, indicated for rapid control of ventricular rate in patients with severe, acute cardiac arrhythmias (irregular rapid heart rate) in critical care settings.

Clinical studies have demonstrated that Rapiblyk® enables safe, effective heart rate control with limited impact on blood pressure and inotropy (heart contractility). Rapiblyk® has a very short half-life delivering a fast onset and offset of action. This provides clinicians with a higher level of precision in life-threatening situations.

Phebra CEO Andre Vlok highlighted how Rapiblyk® strengthens the company's critical care portfolio. "We're proud to bring this potentially life-saving treatment for acute cardiac arrhythmias to Australia," he said. "With a strong clinical track record in Japan, Europe and the US, Rapiblyk® offers new options for managing acute heart conditions. It expands our innovative medicines, addressing key needs of Australian healthcare professionals and patients."

For more product information, go to: <https://www.phebra.com.au/Rapiblyk/pi>

About Phebra

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

At Phebra, we create critical medicines that save and improve lives.

About Rapiblyk

Rapiblyk® is a registered trademark of AOP Orphan Pharmaceuticals GmbH. Rapiblyk® is distributed in Australia by Phebra Pty Ltd under license from AOP Orphan Pharmaceuticals GmbH.

Media contact: Richard Lenarduzzi +61 411 254 390